India has enough HCQ stock to meet demand, and clinical trial results are crucial

New Delhi April 10, 2020: While the government’s partial relaxation of the export ban on hydroxychloroquine (HCQ) has renewed concerns of a possible shortage of the drug in the domestic market, industry executives and healthcare experts Moneycontrol spoke to said India has enough capacities to meet the domestic and global demand. India earns about $40-$50 […]

Continue Reading